AXGN

Axogen, Inc.

AxoGen Inc is a medical technology company dedicated to peripheral nerve repair. It provide products and education to improve surgical treatment algorithms for peripheral nerve injuries.

Axogen, Inc. (AXGN) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Value (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
C-
Factor Score 2.1 / 5.0
Growth
B
Factor Score 3.3 / 5.0
Profitability
B
Factor Score 3.3 / 5.0
Momentum
C+
Factor Score 2.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 78.5
EV / EBITDA -427.9
Rev Growth YoY 26.2%
Gross Margin 74.2%
Price Return 3M 10.3%
Price Return 12M 130.4%
Catalyst Signal 0.00
Market Cap $3.3B
TTM Revenue $266.9M
Price / Sales 12.4
ROE -10.3%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C- (2.1) B (3.3) B (3.3) C+ (2.7) C+ (2.6) C+ (2.8)
2026-11-10 C (2.2) B (3.4) B (3.3) C+ (2.7) C+ (2.6) B- (2.9)
2026-11-03 C (2.3) B (3.3) B (3.3) C+ (2.8) C+ (2.7) B- (2.9)
2026-10-27 C+ (2.5) B- (3.0) B (3.3) B- (2.9) C+ (2.6) B- (2.9)
2026-10-20 C+ (2.6) B- (3.0) B (3.3) B- (3.0) C+ (2.6) B- (2.9)
Page 1 of 8
…